Human thrombin plus 5 per cent ethanolamine oleate injected to sclerose oesophageal varices: A prospective randomized trial

S. Kitano, M. Hashizume, H. Yamaga, H. Wada, Y. Iso, T. Iwanaga, K. Sugimachi

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Fifty cirrhotic Japanese patients with oesophageal varices underwent sclerotherapy in a prospective randomized trial carried out to examine the effects of human thrombin given concomitantly with the sclerosant 5 percent ethanolamine oleate. The two groups (25 patients each) were comparable with regard to size of the oesophageal varices, and the aetiology and severity of the liver disease. Twenty‐five patients, 13 and 12 in the thrombin + and ‐ groups, respectively, had at least one episode of variceal bleeding. The remaining 25 were given prophylactic injections. There was a significantly lower rate of occurrence of bleeding from injection sites when the injection needle was removed at the initial session of sclerotherapy in the thrombin + group, where human thrombin was injected (0·2‐0·3 ml, 100–150 units per injection) just before removal of the injection needle. Endoscopy at 1 week after the initial session showed a significantly (P < 0·05) higher rate of disappearance of red colour signs on varices in the thrombin + group (96 per cent) than in the thrombin ‐ group (72 per cent). Fibrin degradation product E‐fraction (FDP‐E) values increased 1 h, 1 day and 6 days after the initial session of sclerotherapy in the two groups. The rate of increase in FDP‐E values 1 h after sclerotherapy was significantly larger (P < 0·001) in the thrombin + than in the thrombin ‐ group. There was no clinical sign of disseminated intravascular coagulation. Administration of human thrombin plus a sclerosant seems to be useful and efficacious, especially for patients with huge oesophageal varices.

Original languageEnglish
Pages (from-to)715-718
Number of pages4
JournalBritish Journal of Surgery
Volume76
Issue number7
DOIs
Publication statusPublished - Jul 1989

Fingerprint

Esophageal and Gastric Varices
Sclerosis
Thrombin
Sclerotherapy
Injections
Sclerosing Solutions
Fibrin Fibrinogen Degradation Products
Needles
Hemorrhage
ethanolamine oleate
Disseminated Intravascular Coagulation
Varicose Veins
Endoscopy
Liver Diseases
Color

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Human thrombin plus 5 per cent ethanolamine oleate injected to sclerose oesophageal varices : A prospective randomized trial. / Kitano, S.; Hashizume, M.; Yamaga, H.; Wada, H.; Iso, Y.; Iwanaga, T.; Sugimachi, K.

In: British Journal of Surgery, Vol. 76, No. 7, 07.1989, p. 715-718.

Research output: Contribution to journalArticle

Kitano, S. ; Hashizume, M. ; Yamaga, H. ; Wada, H. ; Iso, Y. ; Iwanaga, T. ; Sugimachi, K. / Human thrombin plus 5 per cent ethanolamine oleate injected to sclerose oesophageal varices : A prospective randomized trial. In: British Journal of Surgery. 1989 ; Vol. 76, No. 7. pp. 715-718.
@article{26d958ee7c9f42f9b8e1004b8e608627,
title = "Human thrombin plus 5 per cent ethanolamine oleate injected to sclerose oesophageal varices: A prospective randomized trial",
abstract = "Fifty cirrhotic Japanese patients with oesophageal varices underwent sclerotherapy in a prospective randomized trial carried out to examine the effects of human thrombin given concomitantly with the sclerosant 5 percent ethanolamine oleate. The two groups (25 patients each) were comparable with regard to size of the oesophageal varices, and the aetiology and severity of the liver disease. Twenty‐five patients, 13 and 12 in the thrombin + and ‐ groups, respectively, had at least one episode of variceal bleeding. The remaining 25 were given prophylactic injections. There was a significantly lower rate of occurrence of bleeding from injection sites when the injection needle was removed at the initial session of sclerotherapy in the thrombin + group, where human thrombin was injected (0·2‐0·3 ml, 100–150 units per injection) just before removal of the injection needle. Endoscopy at 1 week after the initial session showed a significantly (P < 0·05) higher rate of disappearance of red colour signs on varices in the thrombin + group (96 per cent) than in the thrombin ‐ group (72 per cent). Fibrin degradation product E‐fraction (FDP‐E) values increased 1 h, 1 day and 6 days after the initial session of sclerotherapy in the two groups. The rate of increase in FDP‐E values 1 h after sclerotherapy was significantly larger (P < 0·001) in the thrombin + than in the thrombin ‐ group. There was no clinical sign of disseminated intravascular coagulation. Administration of human thrombin plus a sclerosant seems to be useful and efficacious, especially for patients with huge oesophageal varices.",
author = "S. Kitano and M. Hashizume and H. Yamaga and H. Wada and Y. Iso and T. Iwanaga and K. Sugimachi",
year = "1989",
month = "7",
doi = "10.1002/bjs.1800760721",
language = "English",
volume = "76",
pages = "715--718",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "John Wiley and Sons Ltd",
number = "7",

}

TY - JOUR

T1 - Human thrombin plus 5 per cent ethanolamine oleate injected to sclerose oesophageal varices

T2 - A prospective randomized trial

AU - Kitano, S.

AU - Hashizume, M.

AU - Yamaga, H.

AU - Wada, H.

AU - Iso, Y.

AU - Iwanaga, T.

AU - Sugimachi, K.

PY - 1989/7

Y1 - 1989/7

N2 - Fifty cirrhotic Japanese patients with oesophageal varices underwent sclerotherapy in a prospective randomized trial carried out to examine the effects of human thrombin given concomitantly with the sclerosant 5 percent ethanolamine oleate. The two groups (25 patients each) were comparable with regard to size of the oesophageal varices, and the aetiology and severity of the liver disease. Twenty‐five patients, 13 and 12 in the thrombin + and ‐ groups, respectively, had at least one episode of variceal bleeding. The remaining 25 were given prophylactic injections. There was a significantly lower rate of occurrence of bleeding from injection sites when the injection needle was removed at the initial session of sclerotherapy in the thrombin + group, where human thrombin was injected (0·2‐0·3 ml, 100–150 units per injection) just before removal of the injection needle. Endoscopy at 1 week after the initial session showed a significantly (P < 0·05) higher rate of disappearance of red colour signs on varices in the thrombin + group (96 per cent) than in the thrombin ‐ group (72 per cent). Fibrin degradation product E‐fraction (FDP‐E) values increased 1 h, 1 day and 6 days after the initial session of sclerotherapy in the two groups. The rate of increase in FDP‐E values 1 h after sclerotherapy was significantly larger (P < 0·001) in the thrombin + than in the thrombin ‐ group. There was no clinical sign of disseminated intravascular coagulation. Administration of human thrombin plus a sclerosant seems to be useful and efficacious, especially for patients with huge oesophageal varices.

AB - Fifty cirrhotic Japanese patients with oesophageal varices underwent sclerotherapy in a prospective randomized trial carried out to examine the effects of human thrombin given concomitantly with the sclerosant 5 percent ethanolamine oleate. The two groups (25 patients each) were comparable with regard to size of the oesophageal varices, and the aetiology and severity of the liver disease. Twenty‐five patients, 13 and 12 in the thrombin + and ‐ groups, respectively, had at least one episode of variceal bleeding. The remaining 25 were given prophylactic injections. There was a significantly lower rate of occurrence of bleeding from injection sites when the injection needle was removed at the initial session of sclerotherapy in the thrombin + group, where human thrombin was injected (0·2‐0·3 ml, 100–150 units per injection) just before removal of the injection needle. Endoscopy at 1 week after the initial session showed a significantly (P < 0·05) higher rate of disappearance of red colour signs on varices in the thrombin + group (96 per cent) than in the thrombin ‐ group (72 per cent). Fibrin degradation product E‐fraction (FDP‐E) values increased 1 h, 1 day and 6 days after the initial session of sclerotherapy in the two groups. The rate of increase in FDP‐E values 1 h after sclerotherapy was significantly larger (P < 0·001) in the thrombin + than in the thrombin ‐ group. There was no clinical sign of disseminated intravascular coagulation. Administration of human thrombin plus a sclerosant seems to be useful and efficacious, especially for patients with huge oesophageal varices.

UR - http://www.scopus.com/inward/record.url?scp=0024361676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024361676&partnerID=8YFLogxK

U2 - 10.1002/bjs.1800760721

DO - 10.1002/bjs.1800760721

M3 - Article

C2 - 2765808

AN - SCOPUS:0024361676

VL - 76

SP - 715

EP - 718

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 7

ER -